Low-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: A Preliminary Study

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Statins are primary treatments for high cholesterol but can cause myopathy, leading to treatment cessation.
• Statin-induced myopathy necessitates expensive alternative therapies, burdening healthcare systems.
• Prior research suggests creatine supplementation as a safe, cost-effective strategy against statin-induced muscle toxicity.

Purpose of the Study:

• To evaluate the tolerability and effectiveness of creatine supplementation in patients experiencing statin myopathy.
• To assess creatine's impact on muscle symptoms and biochemical markers in this patient cohort.

Main Methods:

• Investigated creatine supplementation in consecutive patients with statin myopathy from Cardiology and Neurology clinics.
• Monitored patient adherence, adverse events, and changes in myopathy scores and serum creatine kinase (CK) levels.
• Administered creatine at a dose of 1g three times daily.

Main Results:

• Creatine supplementation was safe and well-tolerated in an elderly population, with high study completion rates.
• A significant reduction in the "myopathy score" was observed, indicating symptom improvement.
• Serum creatine kinase (CK) levels, a marker of muscle damage, were not significantly reduced.
• Effectiveness was noted at a lower dose (1g t.i.d.) than typically prescribed.

Conclusions:

• Creatine supplementation appears beneficial for milder or earlier forms of statin myopathy, particularly when serum CK is not elevated.
• Given its low cost, creatine may offer an alternative to expensive second-line lipid-lowering drugs.
• This approach could reduce the economic burden associated with managing statin-induced muscle side effects.